October DealsAmazon USOctober deal check: compare before you payAmazon US: current deals, useful picks and tech finds.Check DealsWindows FixRecommendedWindows errors stealing your time? Find the fix fastScan stability, cleanup and performance issues.Fix NowOctober DealsAmazon USDeal season is back - check today's better picksAmazon US: current deals, useful picks and tech finds.See Picks×
Skip to content
The Finance Base
The Money Desk · Blog
Re:

How to Determine Whether an Indian Clinical Trial Service Is an Export Under GST

A foreign clinical-trial sponsor does not automatically make an Indian CRO’s services an export under GST. The answer depends on five statutory conditions, especially place of supply and the exact contract and performance facts.
From TheFinanceBase Team6 min to read
Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

An Indian clinical-trial service qualifies as an export of services under GST only if it meets all five conditions in section 2(6) of the IGST Act. A foreign sponsor or payment from abroad is not enough. The place of supply is often the central issue: the result depends on the service being supplied, the trial goods and their custody, the provider’s role, the recipient’s identity, the payment arrangements and the law applicable during the contract period. Read section 2(6) and the related place-of-supply rules in the IGST Act.

Start with the five statutory conditions

Section 2(6) of the Integrated Goods and Services Tax Act, 2017 (IGST Act) defines an export of services through five cumulative conditions. Assess each one against the actual transaction:

  • Supplier: the supplier of the service is located in India.
  • Recipient: the recipient is located outside India.
  • Place of supply: the place of supply is outside India.
  • Payment: payment is received in convertible foreign exchange or in Indian rupees wherever permitted by the Reserve Bank of India.
  • Distinct establishments: the supplier and recipient are not merely establishments of a distinct person under the statutory explanation.

If any one condition fails, the supply does not meet the Act’s definition of an export of services. The IGST Act is the primary source for the definition and related rules.

Identify the supply and the actual recipient

Do not classify a whole clinical-trial relationship by its label alone. A CRO may perform research work, manage trial sites, provide support, or arrange services supplied by other parties. Those activities may need separate analysis if the contracts and performance show materially different deliverables or recipients.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Map the parties and deliverables

Review the master services agreement, work orders, statements of work and invoices. For each material service, identify who contracts to supply it, who is legally and commercially receiving it, who performs it, and who is responsible for the promised result. Include trial sites, investigators, affiliates and subcontractors where they take part in performance. The official Cliantha Research ruling and the Asiatic Clinical Research record concern particular arrangements; neither should be treated as a ruling on every CRO contract.

Check the recipient’s location and corporate relationship

A foreign entity named in a contract is not automatically the recipient for every service. Check which entity receives and uses each deliverable and whether another entity is the real contracting or receiving party. If the recipient is a foreign group company, separately test the distinct-establishment condition rather than assuming that every affiliate transaction is disqualified. CBIC Circular 161/17/2021-GST addresses supplies by an Indian subsidiary or group company to a foreign group company; apply it to the actual corporate structure and transaction. CBIC Circular 161/17/2021-GST.

Why place of supply can decide the result

For cross-border services, section 13 of the IGST Act generally places the supply at the recipient’s location unless a more specific rule applies. Two questions deserve particular attention in a clinical-trial arrangement: whether the service concerns goods physically made available to the provider, and whether the provider is an intermediary.

Trial products and other goods

Section 13(3)(a) addresses services supplied in respect of goods that must be physically made available by the recipient to the supplier, or to a person acting on the supplier’s behalf, to provide the service. Clinical trials may involve investigational products at sites in India. Establish who supplies the product, who holds or handles it, where it is during the work, and how the service depends on its availability. The presence of a drug in India, by itself, should not be treated as conclusive: determine whether the statutory rule applies to the particular service and whether an applicable exception or notification changes the analysis. See section 13 of the IGST Act.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Research on the provider’s own account or intermediary activity

The Act’s intermediary definition covers a broker, agent or other person who arranges or facilitates a supply between two or more persons, while excluding a person who supplies the relevant goods or services on its own account. A CRO responsible for a research deliverable is analytically different from a provider that merely arranges a sponsor’s supply with another provider. Examine the contract, actual responsibilities, and which service is the principal or main supply. CBIC Circular 107/26/2019-GST says intermediary status depends on the facts and circumstances. If the intermediary place-of-supply rule in section 13(8)(b) applies, the place of supply is the supplier’s location; for an Indian supplier, that may prevent the place-of-supply condition for export from being met. CBIC Circular 107/26/2019-GST; CBIC sectoral FAQ.

What the Cliantha ruling does—and does not—establish

In its decision dated 4 May 2019, the Maharashtra Authority for Advance Ruling in Cliantha Research Limited concluded, on the applicant’s facts, that clinical trials and support services performed at the applicant’s facilities in India had a place of supply in India and did not qualify as export services. The ruling is an important example of how the place-of-supply issue has been decided in a particular clinical-research arrangement. It is not a universal rule that every Indian CRO’s services to a foreign sponsor fail the export test. Cliantha Research Limited order; GST Council AAR case index.

Check the later pharmaceutical R&D development for the relevant period

A 2025 Karnataka High Court case record in Iprocess Clinical Marketing concerns clinical trials, sections 13(2) and 13(3)(a), and Notification No. 04/2019-Integrated Tax. The cited judgment record includes an argument about the notification’s scope and retrospective effect; that argument alone does not establish the court’s final holding or the notification’s full effect. Do not rely on the record to claim that all clinical-trial services are exports, or that all are non-exports. For a contract spanning a notification or judgment period, verify the official notification, the full judgment and their effective dates before reaching a conclusion. Iprocess Clinical Marketing judgment record.

Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Support on Ko-Fi

Check how consideration is paid

Trace the consideration against the contract and the statutory payment condition. Record what the foreign recipient owes, what the Indian supplier invoices, what is actually received, and whether payments meet the applicable statutory requirements. Do not infer compliance merely from a foreign-currency invoice or a payment originating abroad.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

If the foreign recipient pays an overseas subcontractor directly for part of the contracted work, examine whether the contract, subcontracted scope and payment satisfy the conditions explained in CBIC Circular 78/52/2018-GST for treating that amount as consideration for export services. The circular does not remove the need to test the other export conditions. CBIC Circular 78/52/2018-GST.

Use a transaction file to reach and support the conclusion

Before deciding how to treat a clinical-trial service, assemble records that let a reviewer follow the supply from contract to performance and payment:

  • Master services agreements, work orders, statements of work and amendments, including the relevant contract dates.
  • Legal identities and locations of the supplier, contracting party, service recipient, sponsor, group entities and any entity using the deliverable.
  • A description of each service and deliverable, the party responsible for it, and the role of the CRO, sites, investigators and subcontractors.
  • Records showing who supplied the investigational product or other goods, where they were held or used, and who had custody during the relevant work.
  • Invoices, payment records, bank documentation and any direct payments by the foreign recipient to overseas subcontractors.
  • The notifications and legal decisions applicable during the period being assessed, including verified official texts where a later development may affect the result.

Then document the five-condition test and the reasoning for the applicable place-of-supply rule for each material service. If the GST treatment affects tax charged, a letter of undertaking (LUT), or a refund position, obtain transaction-specific Indian GST advice. Refund calculations and filing requirements should be checked against the current rules; CBIC publishes the GST refund rules.

Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Leave a Reply

Your email address will not be published. Required fields are marked *

What’s actually slowing this PC down?

Pick the symptom - the matching free tool is one click away.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

More post from the Money Desk

  1. The Money DeskBlogTheFinanceBase09 OCT 267 minMortgage Escrow FAQs: Taxes, Insurance, Shortages, and Refunds
  2. The Money DeskBlogTheFinanceBase09 OCT 265 minHow Mortgage Escrow Accounts Work and What Homeowners Pay For
  3. The Money DeskBlogTheFinanceBase09 OCT 265 minHow to Read a Stock Chart, Volume and Market-Cap Data
Recommended PC Tool
Recommended PC Tool
Crashes, No Sound, or Screen Glitches?Free driver scan
PC Slower Than It Used to Be?Free scan - under a minute

Two free Windows tools

One Free Minute Could Fix That PC

Before you go - each of these free tools takes about a minute and tackles what quietly slows a Windows PC down.

Special offer. View Outbyte info, uninstall instructions, EULA, and Privacy Policy.